Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib Extension Study in Thyroid Eye Disease
NCT06112340Phase 3Recruiting
- Sponsor
- Sling Therapeutics, Inc.
- Start
- Oct 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linsitinib in thyroid eye disease (TED) (2 arms), sponsored by Sling Therapeutics, Inc. Primary endpoint: Percentage of Subjects who are Proptosis Responders at 24 weeks. Started Oct 2023; status: recruiting.
02
Drugs
linsitinib
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06112340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06112340.